A nurse on a telemetry unit is caring for a client who has an irregular radial pulse. Which of the following ECG abnormalities should the nurse recognize as atrial flutter?

Correct Answer: A

Rationale: The correct answer is A because atrial flutter typically presents with an atrial rate of 250-400/min and a ventricular rate that may vary. In this case, an atrial rate of 300/min with QRS complex of 80/min indicates a 3:1 AV block, which is characteristic of atrial flutter. Choice B (absent P waves with irregular QRS) is more indicative of atrial fibrillation. Choice C (ventricular rate of 150/min) does not provide specific information about the atrial activity to diagnose atrial flutter. Choice D (ST elevation) is not typically associated with atrial flutter.

Correct Answer: A

Rationale: The correct action is A: Stop the infusion of blood. This is the first step because the client is experiencing signs of a transfusion reaction, likely an allergic reaction. Stopping the infusion is crucial to prevent further adverse effects. Continuing the infusion could lead to more severe reactions. Giving antihistamines (choice B) would be the next step after stopping the infusion to manage the allergic symptoms. Increasing the infusion rate (choice C) could exacerbate the client's reaction. Monitoring temperature (choice D) is important but not the priority in this situation.

Correct Answer: A

Rationale: Step-by-step rationale: 1. Celecoxib is a selective COX-2 inhibitor used for pain and inflammation. 2. Studies have shown celecoxib increases the risk of cardiac events. 3. This is due to its mechanism of action affecting prostaglandins. 4. Prostaglandins play a role in cardiovascular homeostasis. Summary: - Choice A is correct as cardiac risks are a specific consideration for celecoxib. - Choices B, C, and D are incorrect as celecoxib is not primarily associated with increased risk of GI bleeding, renal failure, or CNS effects.

Correct Answer: A

Rationale: The correct answer is A, Belimumab. Belimumab is a monoclonal antibody that targets B-lymphocyte stimulator protein, specifically approved for systemic lupus erythematosus (SLE). It helps reduce autoantibody production and inflammation in SLE patients. Methotrexate (B), Hydroxychloroquine (C), and Leflunomide (D) are not monoclonal antibodies. Methotrexate is a DMARD, Hydroxychloroquine is an antimalarial, and Leflunomide is a DMARD used for rheumatoid arthritis, not specifically for SLE.

Correct Answer: A

Rationale: The correct answer is A: Colchicine. Colchicine is used to treat acute gout attacks by reducing inflammation and pain caused by uric acid crystals in the joints. It works by inhibiting the inflammatory response to these crystals. Allopurinol, Febuxostat, and Probenecid are used for long-term management of gout by lowering uric acid levels, not for acute attacks. Colchicine is specifically indicated for treating acute gout attacks due to its anti-inflammatory properties.